Researchers from Sinai Health have published a study providing an ultra-detailed look at the organization of a living human cell, providing a new tool that can help scientists around the world better understand what happens during disease.
The new study, published in the journal Nature, was conducted in the laboratory of Dr. Anne-Claude Gingras, a senior investigator at the Lunenfeld-Tanenbaum Research Institute and professor in the Department of Molecular Genetics at the University of Toronto.
U of T researchers to help form national Coronavirus Variants Rapid Response Network indiaeducationdiary.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiaeducationdiary.in Daily Mail and Mail on Sunday newspapers.
Share this article
mRNA vaccine is first fully made-in-Canada vaccine to undergo trials
TORONTO and CALGARY, AB, Dec. 23, 2020 /CNW/ - Providence Therapeutics today announced that Health Canada has provided a Notice of Authorization for its Clinical Trial Application. This permits the Canadian biotech company to begin human clinical trials of its COVID-19 vaccine. PTX-COVID19-B is a messenger RNA (mRNA) vaccine and is the first fully made-in-Canada COVID vaccine to reach this stage of development.
Health Canada s authorization means Phase I clinical trials will begin early in the New Year. Later phase clinical trials are expected to proceed in 2021, subject to regulatory approval.